Home » Prescription Drugs 10 » Lithicarb Eskalith
Indications1.Treatment of mania and hypomania. 2.Lithium may also be tried in the treatment of some patients with recurrent bipolar depression for which treatment with other antidepressants has been unsuccessful. 3.Prophylactic treatment of recurrent affective disorders.Dosage and AdministrationA simple treatment schedule has been evolved which except for some minor variations should be followed whether using LITHICARB FC therapeutically or prophylactically. The minor variations to this schedule depend on the elements of the illness being treated and these are described later.1. In patients of average weight (70kg) an initial dose of 400- 1 200mg of LITHICARB FC may be given as a single daily dose in the morning or on retiring. Alternatively the dose may be divided and given morning and evening. The tablets should not be crushed chewed or swallowed with hot liquids. When changing from other lithium preparations serum lithium levels should first be checked then 2. LITHICARB FC therapy commenced at a daily dose as close as possible to the dose of the other form of lithium. As bioavailability varies from product to product (particularly with regard to retard or slow release preparations) a change of product should be regarded as initiation of new treatment. 3. Four to five days after starting treatment (and never longer than one week) a blood sample should be taken for the estimation of serum lithium level. 4. The objective is to adjust the LITHICARB FC dose so as to maintain the serum lithium level permanently within the diurnal range of 0.5 - 1.5 mmol/L. In practice the blood sample should be taken between 12 and 24 hours after the previous dose of LITHICARB FC. 'Target' serum lithium concentrations at 12 and 24 hours are shown in Table 1.LITHICARB FC tablets are scored therefore they can be divided accurately to provide dosage adjustments as small as 125mg. Serum lithium levels should be monitored weekly until stabilisation is achieved.Table 1. Target serum lithium concentrations "Target" serum lithium concentration (mmol/L) At 12 hours At 24 hours Once daily dosage 0.7 - 1.0 0.5 - 0.8 Twice daily dosage 0.5 - 0.8 4. Lithium therapy should not be initiated unless adequate facilities for routine monitoring of serum concentrations are available. Following stabilisation of serum lithium levels the period between subsequent estimations can be increased gradually but should not normally exceed three months. Additional measurements should be made following alteration of dosage on development of intercurrent disease signs of manic or depressive relapse following significant change in sodium or fluid intake or if signs of lithium toxicity occur. 5. Whilst a high proportion of acutely ill patients may respond within three to seven days of the commencement of LITHICARB FC therapy LITHICARB FC should be continued through any recurrence of the affective disturbance. This is important as the full prophylactic effect may not occur for 6 to 12 months after the initiation of therapy. 6. In patients who show a positive response to LITHICARB FC therapy treatment is likely to be long term. Careful clinical appraisal of the patient should be exercised throughout medication (see Precautions).Treatment of Acute Mania Hypomania and Recurrent Bipolar Depression:It is likely that a higher than normal LITHICARB FC intake may be necessary during an acute phase and divided doses would be required here. Therefore as soon as control of mania or depression is achieved the serum lithium level should be determined and it may be necessary dependent on the results to lower the dose of LITHICARB FC and re-stabilise serum lithium levels. In all other details the described treatment schedule is recommended.Prophylactic Treatment of Recurrent Affective DisordersIt is recommended that the described treatment schedule is followed.Use in the Elderly:In elderly patients or those below 50kg in weight it is recommended that the starting dose be 400mg. Elderly patients may be more sensitive to undesirable effects of lithium and may also require lower doses in order to maintain normal serum lithium levels. It follows therefore that long term patients often require a reduction in dosage over a period of years.Use in Children and AdolescentsNot recommended.
Buy Lithicarb Eskalith and other Prescription Drugs 10 products online
at Medstore.
Buy Online at Medstore - Click Here!

About Lithicarb Eskalith:
Product Type: Prescription Drugs 10
Lithicarb ( Eskalith Generic Lithium Carbonate )
Lithicarb (Eskalith Generic Lithium Carbonate)
Eskalith Generic Lithium Carbonate
250mg
Eskalith Generic Lithium Carbonate Lithicarb

View more
Prescription Drugs 10
Previous Product Next Product
You do not need a prescription to buy our products as we work under the laws of the country we ship from. We do recommend you check with your local customs to see if it is okay to import these products.
Errors and Omissions. We are not responsible for any typographical errors or inaccuracies set forth in this website. The information, prices, and discounts set forth herein are subject to change without notice.
Product Fulfilment : The pharmacy / Fulfilment Centre cannot be held liable for the accuracy of the diagnosis, treatment or medication prescribed or the correct use of products supplied. It lies on the purchaser to use any products supplied under the guidance of a physician.
Product Quality. The Pharmacy / Fulfilment Centre is responsible for ensuring that the correct product, in the correct amount and the correct strength is supplied to the correct patient. Product liability lies solely with the manufacturer.
World Drug News. Government funding crisis in Swaziland disrupts supply of HIV/AIDS supplies. "An acute government funding crisis in Swaziland, Africa's last absolute monarchy, is disrupting supplies of HIV/AIDS drugs and hampering the fight against the virus in the country with the world's highest infection rate, Medecins Sans Frontieres (MSF) said Friday," Reuters reports. "Stocks of testing kits and related chemicals were 'almost dry,' making it next-to-impossible to chart the progress of the 70,000 patients on therapy or more than 130,000 other people carrying the virus, the aid agency said," according to Reuters.
"With 26 percent of its adult population, or more than 200,000 people infected, Swaziland ranks as the most AIDS-affected country," Reuters writes (Cropley, (9/9). In related news, a new report from Swaziland's government "has found that more than half of [30,000 Swazis, mostly women, working] in Swaziland's garment industry are living with HIV, and officials are realizing that the once-hailed promise of manufacturing employment has become a financial and medical nightmare for tens of thousands of Swazi women," PlusNews reports (8/11).
This article was reprinted from kaiserhealthnews.org with permission from the Henry J. Kaiser Family Foundation. Kaiser Health News, an editorially independent news service, is a program of the Kaiser Family Foundation, a nonpartisan health care policy research organization unaffiliated with Kaiser Permanente.
Glez Glucotrol
Gliben Daonil
Gliclazide Glyade
Glimax Amaryl
Glimy Amaryl
GLINATE Starlix
Glinil M Glucovance
GlucoBalance
Glucobay Precose
Glucophage Fortamet
Glucophage (Metformin)
Glucotrol (Glipizide SR)
Glucotrol XL Generic Glipizide
Glucovance Generic Glyburide
GLUMET Glucophage
Glynase Glucotrol
Glynase XL Glucotrol XL
Gonaphene Clomid
GRANICIP KYTRIL
Graniset Kytril
Grief & Pining Formula
Grisactin (Griseofulvin)
GRISOVIN Fulvicin


|